GET THE APP

A potential immunological score might be developed on the basis o | 710
Journal of Clinical & Experimental Dermatology Research

Journal of Clinical & Experimental Dermatology Research
Open Access

ISSN: 2155-9554

+44 1478 350008

A potential immunological score might be developed on the basis of antibody profile analysis in melanomas


2nd International Conference on Clinical Research Cardiology, Ophthalmology & Dermatology

5-7 March 2012 Omaha Marriott, USA

Beatrix Kotlan

Accepted Abstracts: J Clin Exp Dermatol Res

Abstract :

Introduction:This study is focused on a major question of tumor immunology that is to reveal the potential role and capacity of immunocompetent cells found in solid tumors. Objectives:We aimed to develop a new immunoglobulin profile analysis based on our findings on B cells (Tumor infiltrating B lymphocyte, TIL-B) infiltrating malignant melanomas. Methods:Expressed heavy and light chain immunoglobulin variable region gene (VH-JH and Vk-Jk) usage was analysed at DNA level from various melanoma and breast cancer tissues. Cloned and sequenced heavy and light chain immunoglobulin variable region genes were sequenced and comparatively analysed at DNA and amino acid levels with Vector NTI Advance 11, Bioedit 7.0 Alignment editor, ClustalX2.0.11 multiple alignment and grouping TreeView 1.6.6 programs. Tissue samples of melanomas were processed for tissue microarrays (TMA Master for MIRAX Viewer 1.12, 3D Histech) and unique sialilated glycosphingolipides were tested by immunohistochemistry. Results:Comparative sequence data analysis revealed a pattern of immunoglobulin variable region genes with tumor associated antigen binding potentials. GD3 ganglioside expression was tested parallel to other tumorassociated antigens by immunohistochemistry on melanomas. Conclusions:Our data indicate internationally as first that tumor associated sialilated glycosphingolipides are among the target molecules of these TIL-B immunoglobulines. The novel antibody profile analysis reveals important aspects of the patients? cancer related potential anti tumor humoral immune response. We acknowledge:The Harry J. Lloyd Charitable Trust and the previous Fulbright No1206103 grant to B. Kotlan and thank for the contribution of Professor Dr Jozsef Toth, Dr Judit Olasz, Mrs Tunde Illy, Mrs Rozsa Racz.

Top
https://www.olimpbase.org/1937/